ViiV Healthcare’s innovative injectable therapy shows promise in patients with detectable HIV and no prior resistance, offering a potential new avenue for treatment optimization.
London, UK – [Insert Date] – ViiV Healthcare, a global specialist in HIV treatment, announced today that its long-acting injectable antiretroviral therapy, Cabenuva (cabotegravir and rilpivirine), has achieved superior rates of viral suppression compared to daily oral antiretroviral therapy (ART) in adults and adolescents living with HIV-1. The groundbreaking findings stem from the Phase IIIb CROWN study (NCT06694805), a trial designed to evaluate the efficacy of initiating Cabenuva directly in individuals with detectable HIV who have no pre-existing resistance to integrase strand transfer inhibitors (INSTIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs).
The CROWN study met its primary endpoint, demonstrating that participants receiving Cabenuva, administered six times annually, achieved significantly higher rates of viral suppression after six months compared to those on daily oral ART. This outcome marks a significant step forward in the evolution of HIV treatment, potentially offering a more convenient and effective option for a broader patient population.
CROWN Study Unveils Superior Efficacy for Long-Acting Therapy
The CROWN study enrolled approximately 326 participants across eight countries and 85 study sites, including both adults and adolescents living with HIV-1. The trial was specifically designed to address an unmet need in HIV management: the direct initiation of long-acting injectable therapy in individuals who, despite being on treatment, still had detectable levels of the virus and had not previously developed resistance to key classes of antiretrovirals.
"People living with HIV who experience challenges achieving or maintaining viral suppression with daily oral therapy continue to face significant barriers to optimising care," stated Jean van Wyk, Chief Medical Officer at ViiV Healthcare. "The CROWN study was designed to address this important evidence gap. These findings add to the growing body of data around long-acting treatment with Cabenuva and provide important insights into the potential role of this approach for treatment-experienced people living with HIV."
The study’s success in meeting its primary endpoint underscores the potential of Cabenuva not only for maintaining viral suppression in those already suppressed but also for initiating treatment in individuals with detectable viral loads, provided they have no INSTI or NNRTI resistance. It is important to note that the use of Cabenuva in this specific patient population – those with detectable HIV at study entry and no resistance – is currently under investigation and has not yet been approved by regulatory authorities.
Chronology of Cabenuva’s Development and Approval
Cabenuva represents a significant advancement in HIV treatment paradigms. Its journey from concept to clinical application has been marked by rigorous research and strategic regulatory approvals.
- January 2021: The US Food and Drug Administration (FDA) grants approval for long-acting Cabenuva at a monthly dosing schedule. This marked the first long-acting injectable treatment for HIV approved in the United States, offering an alternative to daily oral pills.
- February 2022: The FDA approves a two-monthly dosing schedule for Cabenuva. This further enhanced patient convenience and flexibility, reducing the frequency of clinic visits for injections.
- Subsequent Approvals: The two-monthly combination of cabotegravir and rilpivirine has also received approval in the European Union and Japan. In these regions, it is marketed as two separate drugs: Vocabria (cabotegravir) and Rekambys (rilpivirine). These approvals are for the treatment of HIV-1 infection in adults and adolescents who are virologically suppressed on a stable antiretroviral regimen, have no history of treatment failure, and possess no known or suspected resistance to either component of the therapy.
The CROWN study builds upon previous research, notably the LATITUDE study (NCT03635788). LATITUDE demonstrated that Cabenuva was superior to daily oral therapy in maintaining viral suppression among individuals living with HIV who had achieved viral suppression on standard-of-care oral ART but had a history of adherence challenges. This previous study highlighted the benefits of long-acting therapy for improving adherence and sustained viral control in a specific patient group.
Supporting Data and Market Projections
The clinical success of Cabenuva is further amplified by robust market projections and analyses by GlobalData, a leading data analytics and consulting company and the parent company of Clinical Trials Arena.
According to GlobalData’s patient-based forecast, Cabenuva is anticipated to generate $2.47 billion at its peak in 2030. This impressive financial projection underscores the significant market demand and the perceived value of long-acting HIV treatment options.
Further analysis from GlobalData’s report, "Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast," indicates a positive growth trajectory for the overall HIV market. The seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan) are projected to see the market grow from $26.5 billion in 2023 to $32.1 billion by 2033, representing a compound annual growth rate (CAGR) of 1.9%. The United States is expected to remain the largest market, with sales projected to increase from $23 billion in 2023 to $27.4 billion in 2033, at a CAGR of 1.8%.
The report identifies the increased uptake of long-acting injectable therapies as a primary driver for this market growth, alongside the introduction of novel single-tablet regimens (STRs). This trend highlights a clear shift in treatment preferences towards more convenient and potentially more effective delivery methods.
Official Responses and Clinical Significance
ViiV Healthcare, a company majority-owned by GSK, has consistently emphasized its commitment to developing innovative solutions for people living with HIV. The results from the CROWN study are a testament to this dedication.
"The CROWN study was designed to address an important evidence gap," Jean van Wyk reiterated. "These findings add to the growing body of data around long-acting treatment with Cabenuva and provide important insights into the potential role of this approach for treatment-experienced people living with HIV."
The clinical significance of the CROWN study lies in its exploration of Cabenuva’s efficacy in a population that has historically presented challenges in achieving and maintaining viral suppression with daily oral regimens. By demonstrating superior viral suppression in individuals with detectable HIV and no resistance, the study opens up new possibilities for treatment initiation and management.
Other significant advancements in HIV treatment are also contributing to market growth. Gilead’s biannual injectable Yeztugo (lenacapavir) for pre-exposure prophylaxis (PrEP) has shown remarkable potential. The marketed drug demonstrated 100% efficacy in preventing new HIV infections in the PURPOSE1 Phase III trial, positioning it as a crucial new tool in HIV prevention strategies.
Implications for HIV Treatment and Patient Care
The findings from the CROWN study carry profound implications for the future of HIV treatment and patient care:
- Expanded Treatment Options: The successful demonstration of superior viral suppression in a new patient group could lead to expanded indications for Cabenuva, offering a valuable alternative for individuals who struggle with daily oral medication or who have not achieved optimal viral control.
- Improved Adherence and Quality of Life: Long-acting injectables like Cabenuva significantly reduce the daily burden of medication management, potentially leading to improved adherence rates and a better quality of life for people living with HIV. This can free individuals from the constant reminder of their condition and reduce the stigma associated with daily pill-taking.
- Addressing Treatment Inertia: For patients with detectable HIV and no resistance, initiating a long-acting regimen could potentially overcome treatment inertia and lead to faster achievement of viral suppression. This is crucial for preventing disease progression and onward transmission.
- Future Research Directions: The study’s focus on initiating treatment in patients with detectable viral loads and no resistance paves the way for further research into the optimal timing and patient selection for long-acting injectable therapies. Future studies may explore different resistance profiles and varying levels of viral load at baseline.
- Market Diversification: The growing success of long-acting injectables, alongside novel STRs, indicates a diversification of the HIV treatment landscape. This competition and innovation are likely to benefit patients by driving the development of more effective, convenient, and personalized treatment options.
In conclusion, the CROWN study represents a significant milestone in the ongoing fight against HIV. The superior viral suppression demonstrated by Cabenuva in this trial offers a beacon of hope for individuals who face challenges with traditional daily oral therapies. As ViiV Healthcare continues to explore the full potential of this long-acting injectable, the future of HIV management appears increasingly promising, with a focus on patient-centric solutions that enhance both efficacy and quality of life. The data from CROWN, when combined with ongoing market analyses and the development of other innovative therapies, paints a picture of a dynamic and evolving HIV treatment landscape poised for continued growth and advancement.
About the Author
